A Single Centre, Open, Non-controlled Study in Healthy Subjects to Assess the Eradication of Nasal Carriage of Staphylococcus Aureus (SA) Following a Five Day Course of Mupirocin (Bactroban 2% Nasal Ointment) Using a Broth Enriched Culture Microbiological Assessment.
Phase of Trial: Phase IV
Latest Information Update: 03 Mar 2016
At a glance
- Drugs Mupirocin (Primary)
- Indications Staphylococcal infections
- Focus Therapeutic Use
- Sponsors Destiny Pharma
- 17 Feb 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 11 Nov 2014 New trial record